PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
991
Employees991
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
991
Employees991

PTCT Key Statistics

Market cap
6.38B
Market cap6.38B
Price-Earnings ratio
-32.82
Price-Earnings ratio-32.82
Dividend yield
Dividend yield
Average volume
2.15M
Average volume2.15M
High today
$77.93
High today$77.93
Low today
$73.01
Low today$73.01
Open price
$73.72
Open price$73.72
Volume
3.14M
Volume3.14M
52 Week high
$87.50
52 Week high$87.50
52 Week low
$43.18
52 Week low$43.18

Stock Snapshot

PTC Therapeutics(PTCT) stock is priced at $76.85, giving the company a market capitalization of 6.38B. It carries a P/E multiple of -32.82.

On 2026-05-11, PTC Therapeutics(PTCT) stock traded between a low of $73.01 and a high of $77.93. Shares are currently priced at $76.85, which is +5.3% above the low and -1.4% below the high.

The PTC Therapeutics(PTCT)'s current trading volume is 3.14M, compared to an average daily volume of 2.15M.

During the past year, PTC Therapeutics(PTCT) stock moved between $43.18 at its lowest and $87.50 at its peak.

During the past year, PTC Therapeutics(PTCT) stock moved between $43.18 at its lowest and $87.50 at its peak.

PTCT News

TipRanks 12h
PTC Therapeutics price target raised to $89 from $80 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on PTC Therapeutics (PTCT) to $89 from $80 and keeps an Overweight rating on the shares. The firm up...

Simply Wall St 16h
Why PTC Therapeutics Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$86...

Why PTC Therapeutics Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance
TipRanks 3d
PTC Therapeutics’ Earnings Call Highlights Sephience Surge

PTC Therapeutics ((PTCT)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and po...

Analyst ratings

64%

of 14 ratings
Buy
64.3%
Hold
28.6%
Sell
7.1%

More PTCT News

TipRanks 4d
PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 6d
Assessing PTC Therapeutics Valuation As Rare Disease Growth Narrative Points To Potential Undervaluation

Advertisement Stock performance snapshot and recent context PTC Therapeutics (PTCT) has drawn investor attention after recent trading, with the stock last clo...

Assessing PTC Therapeutics Valuation As Rare Disease Growth Narrative Points To Potential Undervaluation

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.